Literature DB >> 1566575

NYVAC: a highly attenuated strain of vaccinia virus.

J Tartaglia1, M E Perkus, J Taylor, E K Norton, J C Audonnet, W I Cox, S W Davis, J van der Hoeven, B Meignier, M Riviere.   

Abstract

A highly attenuated vaccinia virus strain, NYVAC (vP866), was derived from a plaque-cloned isolate of the Copenhagen vaccine strain by the precise deletion of 18 open reading frames (ORFs) from the viral genome. Among the ORFs deleted from NYVAC (vP866) are two genes involved in nucleotide metabolism, the thymidine kinase (ORF J2R) and the large subunit of the ribonucleotide reductase (ORF I4L); the gene encoding the viral hemagglutinin (ORF A56R); the remnant (ORF A26L) of a highly expressed gene responsible for the formation of A-type inclusion bodies; the disrupted gene (ORFs B13R/B14R) normally encoding a serine protease inhibitor; and a block of 12 ORFs bounded by two known viral host range regulatory functions (ORFs C7L through K1L). Within this block a secretory protein (ORF N1L) implicated in viral virulence and a functional complement 4b binding protein (ORF C3L) are encoded. The ORFs were deleted in a manner which prevents the synthesis of undesirable novel gene products. The attenuation characteristics of the derived NYVAC strain were compared in in vitro and in vivo studies with those of the Western Reserve (WR) laboratory strain, the New York City Board of Health vaccine strain (Wyeth), the parental plaque-cloned isolate (VC-2) of the Copenhagen vaccine strain used to derive NYVAC, and the avipox virus canarypox (ALVAC), which is naturally restricted for replication to avian species. The NYVAC strain was demonstrated to be highly attenuated by the following criteria: (a) no detectable induration or ulceration at the site of inoculation on rabbit skin; (b) rapid clearance of infectious virus from the intradermal site of inoculation on rabbit skin; (c) absence of testicular inflammation in nude mice; (d) greatly reduced virulence as demonstrated by the results of intracranial challenge of both 3-week-old or newborn mice; (e) greatly reduced pathogenicity and failure to disseminate in immunodeficient (nude or cyclophosphamide treated) mice; and (f) dramatically reduced ability to replicate on a variety of human tissue culture cells. Despite these highly attenuated characteristics, the NYVAC strain, as a vector, retains the ability to induce strong immune responses to extrinsic antigens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1566575     DOI: 10.1016/0042-6822(92)90752-b

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  145 in total

1.  Recombinant vaccinia viruses. Design, generation, and isolation.

Authors:  C C Broder; P L Earl
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

2.  Nipah virus: vaccination and passive protection studies in a hamster model.

Authors:  V Guillaume; H Contamin; P Loth; M-C Georges-Courbot; A Lefeuvre; P Marianneau; K B Chua; S K Lam; R Buckland; V Deubel; T F Wild
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

3.  Species specificity of protein kinase r antagonism by cytomegalovirus TRS1 genes.

Authors:  Stephanie J Child; Greg Brennan; Jacquelyn E Braggin; Adam P Geballe
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

4.  Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo.

Authors:  Fatema A Legrand; Paulo H Verardi; Kenneth S Chan; Yue Peng; Leslie A Jones; Tilahun D Yilma
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-10       Impact factor: 11.205

5.  Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.

Authors:  Igor M Belyakov; Vladimir A Kuznetsov; Brian Kelsall; Dennis Klinman; Marcin Moniuszko; Michael Lemon; Phillip D Markham; Ranajit Pal; John D Clements; Mark G Lewis; Warren Strober; Genoveffa Franchini; Jay A Berzofsky
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

6.  A comparison of the effect of molluscum contagiosum virus MC159 and MC160 proteins on vaccinia virus virulence in intranasal and intradermal infection routes.

Authors:  Sunetra Biswas; Geoffrey L Smith; Edward J Roy; Brian Ward; Joanna L Shisler
Journal:  J Gen Virol       Date:  2018-02       Impact factor: 3.891

7.  Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination.

Authors:  Garilyn M Jentarra; Michael C Heck; Jin Won Youn; Karen Kibler; Jeffrey O Langland; Carole R Baskin; Olga Ananieva; Yung Chang; Bertram L Jacobs
Journal:  Vaccine       Date:  2008-04-08       Impact factor: 3.641

Review 8.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

9.  A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.

Authors:  Kenji Someya; Ke-Qin Xin; Kazuhiro Matsuo; Kenji Okuda; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.

Authors:  Jun Liu; Qigui Yu; Geoffrey W Stone; Feng Yun Yue; Nicholas Ngai; R Brad Jones; Richard S Kornbluth; Mario A Ostrowski
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.